| Home | E-Submission | Sitemap | Contact Us |  
top_img

Introduction of Vaccinomics to Develop Personalized Vaccines in Light of Changes the Usage of Hantavax(R)
Jong-Myon Bae
Department of Preventive Medicine, Jeju National University School of Medicine, Jeju, Korea
Corresponding Author: Jong-Myon Bae ,Tel: +82-64-755-5567, Fax: +82-725-2593, Email: jmbae@jejunu.ac.kr
Received: January 6, 2019;  Accepted: August 2, 2019.
ABSTRACT
The Ministry of Food and Drug Safety of the Republic of Korea made an official announcement in March 2018 that the total number of inoculations of Hantavax??would change from 3 to 4. Some aspects of this decision remain controversial. Based on the characteristics of Hantaan virus (HTNV) and its role in the pathogenesis of hemorrhagic fever with renal syndrome, it might be difficult to develop an effective and safe HTNV vaccine through the isolate-inactivate-inject paradigm. With the development of high-throughput 'omics' technologies in the 21st century, vaccinomics has been introduced. While the goal of vaccinomics is to develop equations to describe and predict the immune response, it could also serve as a tool for developing new vaccine candidates and individualized approaches to vaccinology. Thus, the possibility of applying the innovative field of vaccinomics to develop a more effective and safer HTNV vaccine should be considered.
Key words: Hantaan virus; Hemorrhagic fever with renal syndrome; Synthetic vaccines; Immunogenetics; Precision medicine
TOOLS
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
CrossRef TDM  CrossRef TDM
  E-Mail
Share:      
METRICS
0
Crossref
0
Scopus
55
View
0
Download
  Facebook
  Twitter
Editorial Office
Graduate School of Public Health, Seoul National University
1 Gwanak-ro, Gwanak-gu, Seoul 08826, Korea
Tel : +82-2-740-8328   Fax : +82-2-764-8328   E-mail: jpmphe@gmail.com
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © 2019 by Korean Society for Preventive Medicine. All rights reserved.                 powerd by m2community